Introduction
NAFLD, obesity, inflammation, cirrhosis, fibrosis, liver injury, NASH
OBESITY, INFLAMMATION, DISEASE, CIRRHOSIS, RECRUITMENT, FIBROSIS, LIVER DISEASE, NON-ALCOHOLIC FATTY LIVER DISEASE, PATHOPHYSIOLOGY, ADHESION
Non-alcoholic fatty liver disease (NAFLD) is a progressive disease with associated morbidity and mortality, and is the most common cause of liver disease, with an increasing global prevalence of 25% linked to the global epidemic of obesity and type 2 diabetesPersistent inflammation resulting from liver injury drives progression to fibrosis, cirrhosis and HCCA key protein in promoting the recruitment of leukocytes to liver tissue is amine oxidase copper-containing 3 (AOC3), formerly known as copper-dependent semicarbazide-sensitive amine oxidase (SSAO) or vascular adhesion protein-1Several lines of evidence, including its enzymatic activity and role in leukocyte recruitment, implicate AOC3 in the pathophysiology of NASHHerein, we report results of a randomised, placebo-controlled Phase IIa trial that assessed the safety, tolerability and pharmacodynamics of different doses of orally administered BI 1467335 during a 12-week treatment period, compared with placebo, in patients with clinical evidence of NASH.